About ALX Oncology Inc.
ALX Oncology is a clinical-stage biotechnology company advancing cancer therapies by boosting the immune system.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Founded
- 2015
- Company type
- Public Company
- Company profile name
- ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications.
Specialties
- Immuno-Oncology
- Novel Biologics
- Research and Development
- Innovation
- and CD47
Company locations
323 Allerton Ave, South San Francisco, California 94080, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 7,131
- People linked to this company
- 61
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.